The great gene-patent debate contines: Does it help or hinder research?

An ongoing legal battle over gene patents has led many scientists to ask whether such claims help or hinder research. That question will be debated once more on 20 July when Myriad Genetics, a diagnostic company in Salt Lake City, Utah, returns to the US courts to argue that its patents on the BRCA1 and BRCA2 gene variants — linked to inherited breast and ovarian cancer — are valid. Currently, the patents give Myriad exclusive rights to conduct diagnostic tests on the genes. The judges are expected to issue an opinion by late summer. The case is important because thousands of genes have been patented in the United States, and no one is sure what will happen if the judges rule Myriad’s patents invalid. Nature examines what the Myriad case means to biotechnology and genetic medicine.

View the original article here: The great gene-patent debate – Nature.com

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
seralinistud

Gilles-Éric Séralini: Activist professor and face of anti-GMO industry

The French biologist and his research team--funded by the Rodale ...
vandana shiva

Vandana Shiva: ‘Rock Star’ of GMO protest movement has anti-science history

In a 2012 interview, Bill Moyers referred to Vandana Shiva as ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend